Top

Gepubliceerd in:

2009 | OriginalPaper | Hoofdstuk

19 Medicamenteuze behandeling

Auteurs : Theo Ingenhoven, Thomas Rinne

Gepubliceerd in: Handboek persoonlijkheidspathologie

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Sinds de late jaren zeventig van de vorige eeuw is er sprake van een opmerkelijk groeiend optimisme ten aanzien van de effectiviteit van farmacotherapeutische interventies bij patiënten met een persoonlijkheidsstoornis. Maar is dit optimisme gerechtvaardigd?

vorige hoofdstuk 18 Dialectische gedragstherapie

volgende hoofdstuk 20 Een zorgprogramma voor persoonlijkheidsstoornissen en aanverwante persoonlijkheidsproblemen

Akiskal, H.S. (1994). The temperamental borders of affective disorders. Acta Psychiatrica Scandinavica Suppl, 379, 32-37.

Akiskal, H.S., Hantouche, E.G. & Allilaire, J.F. (2003). Bipolar II with and without cyclothymic temperament: ‘dark’ and ‘sunny’ expressions of soft bipolarity. Journal of Affective Disorders, 73, 49-57.

APA (American Psychiatric Association) (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry, 158, 1-52.

Bogenschutz, M.P. & George, N.H. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104-109.

Cloninger, C.R. (1987). A systemic method for clinical description and classification of personality variants. A proposal. Archives of General Psychiatry, 44, 573-588.

Cloninger, C.R., Svrakic, D.M. & Przybeck, T.R. (1993). A psychological model of temperament and character. Archives of General Psychiatry, 50, 975-990.

Coccaro, E.F. & Kavoussi, R.J. (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry, 54, 1081-1088.

Cornelius, J.R., Soloff, P.H., George, A., Ulrich, R.F. & Perel, J.M. (1993). Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Psychopharmacological Bulletin, 29, 333-337.

Cornelius, J.R., Soloff, P.H., Perel, J.M. & Ulrich, R.F. (1993). Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. American Journal of Psychiatry, 150, 1843-1848.

Cowdry, R.W. & Gardner, D.L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111-119.

De la Fuente, J.M. & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479-486.

Farwell, W.R., Stump, T.E., Wang, J., Tafesse, E., L’Italien, G. & Tierney, W. M. (2004). Weight gain and new onset diabetes associated with olanzapine and risperidone. Journal of General Internal Medicine, 19, 1200-1205.

Gardner, D.L. & Cowdry, R.W. (1985). Alprazolam-induced dyscontrol in borderline personality disorder. American Journal of Psychiatry, 142, 98-100.

Gardner, D.L. & Cowdry, R.W. (1986). Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of Clinical Psychopharmacology, 6, 236-239.

Gardner, D.L. & Cowdry, R.W. (1986). Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. American Journal of Psychiatry, 143, 519-522.

Gitlin, M.J. (1993). Pharmacotherapy of personality disorders: conceptual framework and clinical strategies. Journal of Clinical Psychopharmacology, 13, 343-353.

Goldberg, S.C., Schulz, S.C., Schulz, P.M., Resnick, R.J., Hamer, R.M. & Friedel, R.O. (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Archives of General Psychiatry, 43, 680-686.

Hollander, E., Allen, A., Lopez, R.P., Bienstock, C.A., Grossman, R., Siever, L.J., e.a. (2001). A preliminary double-blind, placebo-controled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry, 62, 199-203.

Hollander, E., Swann, A.C., Coccaro, E.F., Jiang, P. & Smith, T.B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162, 621-624.

Hollander, E., Tracy, K.A., Swann, A.C., Coccaro, E.F., McElroy, S.L., Wozniak, P., e.a. (2003). Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology, 28, 1186-1197.

Koenigsberg, H.W., Reynolds, D., Goodman, M., New, A.S., Mitropoulou, V., Trestman, R.L., e.a. (2003). Risperidone in the treatment of schizotypal personality disorder. Journal of Clinical Psychiatry, 64, 628-634.

Liebowitz, M.R., Quitkin, F.M., Steward, J.W., McGrath, P.J., Harrison, W.M., Markowitz, J.S., e.a. (1988). Antidepressant specificity in atypical depression. Archives of General Psychiatry, 45, 129-137.

Links, P.S., Steiner, M., Boiago, I. & Irwin, D. (1990). Lithium therapy for borderline patients: preliminaryfindings. Journal of Personality Disorders, 4, 173-181.

Loewe, T.H., Nickel, M.K., Meuhlbacher,M., Kaplan, P., Nickel, C., Kettler, C., e.a. (2006). Topiramate treatment for women with borderline personality disorder. Journal of Clinical Psychopharmacology, 26, 61-66.

Montgomery, S.A. & Montgomery, D. (1982). Pharmacological prevention of suicidal behaviour. Journal of Affective Disorders, 4, 291-298.

Montgomery, S.A., Roy, D. & Montgomery, D.B. (1983). The prevention of recurrent suicidal acts. British Journal of Clinical Pharmacology, 15 Suppl 2, 183S-188S.

Nickel, M.K., Nickel, C., Kaplan, P., Lahmann, C., Muhlbacher, M., Tritt, K., e.a. (2005). Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controled study. Biological Psychiatry, 57, 495-499.

Nickel, M.K., Nickel, C., Mitterlehner, F.O., Tritt, K., Lahmann, C., Leiberich, P.K., e.a. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controled study. Journal of Clinical Psychiatry, 65, 1515-1519.

Nickel, M.K., Meuhlbacher, M., Nickel, C., Kettler, C., Gil, F.P., Bachler, E., e.a. (2006). Aripiprazole in the treatment of patients with borderline personality disorder; a double-blind, placebo-controled study. American Journal of Psychiatry, 163, 833-838.

Parsons, B., Quitkin, F.M., McGrath, P.J., Stewart, J.W., Tricamo, E., Ocepek-Welikson, K., e.a. (1989). Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacological Bulletin, 25, 524-534.

Philipsen, A., Schmahl, C. & Lieb, K. (2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196-199.

Rinne, T., van den, B.W., Wouters, L. & Dyck, R. van (2002). SSRI treatment of borderline personality disorder: a randomized, placebo-controled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048-2054.

Salzman, C., Wolfson, A.N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., e.a. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23-29.

Siever, L.J. & Davis, K.L. (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry, 148, 1647-1658.

Simpson, E.B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J. & Pearlstein, T. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379-385.

Soler, J., Pascual, J.C., Campins, M.J., Barrachina, J., Puigdemont, D., Alvarez, E. & Perez, V. (2005). Double-blind, placebo-controled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221-1224.

Soloff, P.H. (1998). Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bulletin of the Menninger Clinic, 62, 195-214.

Soloff, P.H. (2000). Psychopharmacology of borderline personality disorder. The Psychiatric Clinics of North America, 23, 169-92, ix.

Soloff, P.H., Cornelius, J., George, A., Nathan, S., Perel, J.M. & Ulrich, R.F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry, 50, 377-385.

Soloff, P.H., George, A., Nathan, R.S., Schulz, P.M. & Perel, J.M. (1986a). Paradoxical effects of amitriptyline on borderline patients. American Journal of Psychiatry, 143, 1603-1605.

Soloff, P.H., George, A., Nathan, R. S., Schulz, P. M., Ulrich, R.F. & Perel, J.M. (1986b). Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Archives of General Psychiatry, 43, 691-697.

Soloff, P.H., George, A., Nathan, S., Schulz, P. M., Cornelius, J.R., Herring, J. & Perel, J.M. (1989). Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. Journal of Clinical Psychopharmacology, 9, 238-246.

Trestman, R.L., Keefe, R.S., Mitropoulou, V., Harvey, P.D., deVegvar, M.L., Lees-Roitman, S., e.a. (1995). Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research, 59, 127-136.

Tritt, K., Nickel, C., Lahmann, C., Lieberich, P.K., Rother, W.K., Loew, T.H., e.a. (2005). Lamotrigine treatment of aggression in female borderline patients: a randomized, double-blind, placebo-controled study. Journal of Psychofarmacology, 19(3), 287-291.

Zanarini, M.C. & Frankenburg, F.R. (2001). Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controled pilot study. Journal of Clinical Psychiatry, 62, 849-854.

Zanarini, M.C. & Frankenburg, F.R. (2003). Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controled pilot study. American Journal of Psychiatry, 160, 167-169.

Zanarini, M.C., Frankenburg, F.R. & Parachini, E.A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903-907.

Titel: 19 Medicamenteuze behandeling
Auteurs: Theo Ingenhoven
Thomas Rinne
Uitgeverij: Bohn Stafleu van Loghum
Boek: Handboek persoonlijkheidspathologie
Print ISBN: 978-90-313-6112-0

Elektronisch ISBN: 978-90-313-6821-1

Copyright: 2009
DOI: https://doi.org/10.1007/978-90-313-6821-1_19

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen